The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Open accessAbstract
Cancer is nowadays recognised as a genetic and epigenetic disease. Much effort has been devoted in the last 30 years to the elucidation of the 'classical' oncogenes and tumour-suppressor genes involved in malignant cell transformation. However, since the acceptance that major disruption of DNA methylation, histone modification and chromatin compartments are a common hallmark of human cancer, epigenetics has come to the fore in cancer research. One piece is still missing from the story: are the epigenetic genes themselves driving forces on the road to tumorigenesis? We are in the early stages of finding the answer, and the data are beginning to appear: knockout mice defective in DNA methyltransferases, methyl-CpG-binding proteins and histone methyltransferases strongly affect the risk of cancer onset; somatic mutations, homozygous deletions and methylation-associated silencing of histone acetyltransferases, histone methyltransferases and chromatin remodelling factors are being found in human tumours; and the first cancer-prone families arising from germline mutations in epigenetic genes, such as hSNF5/INI1, have been described. Even more importantly, all these 'new' oncogenes and tumour-suppressor genes provide novel molecular targets for designed therapies, and the first DNA-demethylating agents and inhibitors of histone deacetylases are reaching the bedside of patients with haematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Self-citationLoss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
Chromosomal Instability and Tumors Promoted by DNA Hypomethylation
Eden, A., Gaudet, F., Waghmare, A., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083557 · Cited by 1,399
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Rhee, I., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,039
Valk-Lingbeek, M. E., Bruggeman, S. W. M., & van Lohuizen, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.005 · Cited by 743
Suppression of intestinal neoplasia by DNA hypomethylation
Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Edward Jung, W., Li, E., Weinberg, R. A., & Jaenisch, R. (1995) · Cell · doi:10.1016/0092-8674(95)90329-1 · Cited by 710
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISM
Esteller, M. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095832 · Cited by 549
Self-citationMTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer
Fujita, N., Jaye, D. L., Kajita, M., Geigerman, C., Moreno, C. S., & Wade, P. A. (2003) · Cell · doi:10.1016/s0092-8674(03)00234-4 · Cited by 510
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
Bradbury, C. A., Khanim, F. L., Hayden, R., Bunce, C. M., White, D. A., Drayson, M. T., Craddock, C., & Turner, B. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403910 · Cited by 404
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.
Fahrner, J. A., Eguchi, S., Herman, J. G., & Baylin, S. B. (2002) · PubMed · Cited by 399
DNA Binding Selectivity of MeCP2 Due to a Requirement for A/T Sequences Adjacent to Methyl-CpG
Klose, R. J., Sarraf, S. A., Schmiedeberg, L., McDermott, S. M., Stancheva, I., & Bird, A. P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.07.021 · Cited by 344
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer
Ballestar, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg604 · Cited by 320
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
Self-citationOpposing effects of DNA hypomethylation on intestinal and liver carcinogenesis
Yamada, Y., Jackson-Grusby, L., Linhart, H., Meissner, A., Eden, A., Lin, H., & Jaenisch, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506612102 · Cited by 245
Fraga, M. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg249 · Cited by 238
The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability
Riccio, A., Aaltonen, L. A., Godwin, A. K., Loukola, A., Percesepe, A., Salovaara, R., Masciullo, V., Genuardi, M., Paravatou-Petsotas, M., Bassi, D. E., et al. (1999) · Nature Genetics · doi:10.1038/15443 · Cited by 209
Zebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
DNA methylation and cancer therapy: new developments and expectations
Esteller, M. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000147383.04709.10 · Cited by 183
Self-citationDeficiency of Mbd2 suppresses intestinal tumorigenesis
Sansom, O. J., Berger, J., Bishop, S. M., Hendrich, B., Bird, A., & Clarke, A. R. (2003) · Nature Genetics · doi:10.1038/ng1155 · Cited by 176
Towards the Human Cancer Epigenome: A First Draft of Histone Modifications
Fraga, M. F., & Esteller, M. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2113 · Cited by 171
Self-citationHistone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes
Gibbons, R. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi106 · Cited by 155
Paz, M. F. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg226 · Cited by 127
Mutations and Deletions of the CBP Gene in Human Lung Cancer
Kishimoto, M., Kohno, T., Okudela, K., Otsuka, A., Sasaki, H., Tanabe, C., Sakiyama, T., Hirama, C., Kitabayashi, I., Minna, J. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.512.11.2 · Cited by 117
Ionov, Y., Matsui, S., & Cowell, J. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307276101 · Cited by 113
Raaphorst, F. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi111 · Cited by 89
Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia.
Lee, D. W., Zhang, K., Ning, Z. Q., Raabe, E. H., Tintner, S., Wieland, R., Wilkins, B. J., Kim, J. M., Blough, R. I., & Arceci, R. J. (2000) · PubMed · Cited by 87
Herranz, M., Martín‐Caballero, J., Fraga, M. F., Ruı́z-Cabello, J., Flores, J. M., Desco, M., Márquez, V. E., & Esteller, M. (2005) · Blood · doi:10.1182/blood-2005-05-2033 · Cited by 72
Self-citationTranscriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells
Medina, P. P., Carretero, J., Ballestar, E., Angulo, B., López‐Ríos, F., Esteller, M., & Sánchez‐Céspedes, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi091 · Cited by 64
Self-citationÖzdağ, H., Batley, S. J., Försti, A., Iyer, N. G., Daigo, Y., Boutell, J. M., Arends, M. J., Ponder, B. A. J., Kouzarides, T., & Caldas, C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600554 · Cited by 60
Breast cancer metastasis suppressor 1: Update
Meehan, W. J., & Welch, D. R. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022542519586 · Cited by 56
Bader, S. A., Walker, M., McQueen, H. A., Sellar, R., Oei, E., Wopereis, S., Zhu, Y., Peter, A., Bird, A. P., & Harrison, D. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206574 · Cited by 37
MBD2 deficiency does not accelerate p53 mediated lymphomagenesis
Sansom, O. J., Bishop, S. M., Bird, A. P., & Clarke, A. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208166 · Cited by 22
Cited by
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Self-citationEnvironmental epigenomics and disease susceptibility
Jirtle, R. L., & Skinner, M. K. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2045 · Cited by 2,492
The natural history of cervical HPV infection: unresolved issues
Woodman, C. B. J., Collins, S. I., & Young, L. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2050 · Cited by 1,033
Telomeres, lifestyle, cancer, and aging
Shammas, M. A. (2011) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32834121b1 · Cited by 681
Global Levels of Histone Modifications Predict Prognosis in Different Cancers
Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., & Kurdistani, S. K. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080874 · Cited by 508
Metadata
- Authors
- Esteller, M.
- Venue
- British Journal of Cancer
- Published
- 2006-01
- Volume
- 94
- Issue
- 2
- Pages
- 179-183
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2126427849
- Cited by
- 284
- References
- 38
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.